Navigation Links
American Brain Tumor Association Supports $2 Million Glioblastoma Research Project

Chicago, IL (PRWEB) September 03, 2014

The American Brain Tumor Association (ABTA), in conjunction with the Brain Tumor Funder’s Collaborative (BTFC), is awarding a $2 million research grant to explore commonalities among long-term glioblastoma survivors around the world.

Glioblastoma is a common and aggressive type of brain tumor most prevalent in adults ages 45-65, and affects more men than women. This highly malignant tumor’s octopus-like tentacles make it difficult to remove completely during surgery, and with current treatments, median survival is about 14.6 months. A small percentage of patients experience better outcomes and become long-term survivors.

The Brain Tumor Funders’ Collaborative—a strategic partnership among advocacy organizations like the ABTA and private philanthropic groups—initiated a call for research proposals to investigate why only a minority of glioblastoma (GBM) patients achieves long-term survival.

The researchers aim to understand the basis for long-term survival with glioblastoma by comprehensively studying patient histories, tumor characteristics at the molecular genetic level, and effects of treatment. To do this, the researchers identified a large group of more than 300 patients who have survived glioblastoma for more than five years. Understanding the shared characteristics of long-term surviving patients allows for better understanding of the biology of this deadly disease, and will ultimately lead to improved treatments for all patients.

“We are proud to partner in this global initiative and support collaborative science which is vital to furthering our understanding of the characteristics of survivors and potentially uncover new research directions,” said Elizabeth M. Wilson, MNA, ABTA president and CEO. “Collaborations such as these support the ABTA’s mission to advance the understanding and treatment of brain tumors in an effort to improve, extend and ultimately save lives.”

The recipient of the BTFC grant is a research consortium led by the European Organization for Research and Treatment of Cancer (EORTC) and the Brain Tumor Center at the University Hospital in Zurich. The consortium, comprised of more than 20 Neuro-oncology Centers of Excellence across the globe, include researchers in Europe, the United States and Canada.

The project will be managed by Michael Weller, M.D., of the University Hospital Zurich and Patrick Yung Wen, M.D. of the Dana Farber Cancer Institute, in support of the EORTC.

About the American Brain Tumor Association
Founded in 1973, the American Brain Tumor Association was first and is now the only national organization committed to funding brain tumor research and providing information and education on all tumor types and all age groups. For more information, visit or call 800-886-ABTA (2282).

About the Brain Tumor Funders’ Collaborative
Inaugurated in 2003, the Brain Tumor Funders’ Collaborative (BTFC) is a strategic partnership among private philanthropic and advocacy organizations in the US and Canada to pool their resources and focus their research dollars toward advancing the understanding and treatment of brain tumors. The five members of the BTFC are: the American Brain Tumor Association, Brain Tumour Foundation of Canada, Children’s Brain Tumor Foundation, James S. McDonnell Foundation, and the Sontag Foundation.

About the European Organisation for Research and Treatment of Cancer
The European Organisation for Research and Treatment of Cancer (EORTC) is an International non-profit association (AISBL) founded in 1962 and established under the laws of Belgium. The aims of EORTC are to develop, conduct, coordinate, and stimulate translational and clinical research in Europe to improve the management of cancer and related problems by increasing survival but also patient quality of life. EORTC is both multinational and multidisciplinary, and the EORTC network comprises over 300 hospitals and cancer centers in over 30 countries, including about 2,500 collaborators from all disciplines involved in cancer treatment and research. The primary aim of the EORTC Brain Tumor Group (BTG) is to conduct, develop, coordinate, and stimulate clinical and translational research for the treatment of brain tumors and metastases.

# # #

Read the full story at

Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related medicine news :

1. American Healthcare Documentation Professionals Group (AHDPG) Launches Free-Tuition Guarantee for Its ICD-10 Medical Coding Bridge Program
2. American Pain Society Returns with REMS Training at PAINWeek 2014 in Las Vegas
3. Pro Player Health Alliance Confirms Big Name Speakers at 2015 American Sleep and Breathing Academy Conference
4. Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans
5. Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing
6. Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5%
7. North American Seminars Master Clinicians Advanced Shoulder Course Receives PT Continuing Education Course Approval in Georgia, Pennsylvania, Massachusetts and Virginia
8. As Interest in Saunas Increases, the North American Sauna Society Increases Outreach to Provide Education on History, Design, and Culture
9. North American Seminars Online PT Continuing Education Course, Examination and Treatment of the SI Joint, Receives Continuing Education Approval in NJ, CA, IL, PA, & TX
10. There are many reasons why Americans' exercise levels have declined - Meet an executive that refuses to sit still with his TrekDesk Treadmill Desk even in a sedentary job
11. American Telemedicine Association Issues Clinical Guidelines for Telepathology
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... The men and ... nonprofit healthcare organizations in the country. They have overseen financial turnarounds, shown commitment ... advance the healthcare industry as a whole through their advocacy and professional efforts. ...
(Date:11/27/2015)... ... ... Indosoft Inc., developer and distributor of the world-class Asterisk ... Term Support) into its Q-Suite 5.10 product line. , Making the change to ... of Asterisk that will receive not only security fixes, but feature and bug ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... system for diagnostic imaging in the Waterloo region. Using the Ocean Platform, family ... tests directly from their electronic medical record (EMR) without the need for redundant ...
(Date:11/26/2015)... ... 2015 , ... Jobs in hospital medical laboratories and in the imaging field ... agency Aureus Medical Group . These fields, as well as travel ... for healthcare jobs through the company’s website, , The leading healthcare ...
(Date:11/26/2015)... , ... November 26, 2015 , ... ... set of retro-fused, self-animating trailer titles with ProTrailer: Vintage. This newly styled ProTrailer ... classically-influenced trailer titles work with any font, giving users limitless opportunities to stylize ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... 26, 2015 ... the "2016 Global Tumor Marker Testing ... and Sales Segment Forecasts, Innovative Technologies, Instrumentation ... to their offering. --> ... "2016 Global Tumor Marker Testing Market: ...
(Date:11/26/2015)... , November 26, 2015 ... new combination approach blends immunotherapy with Bremachlorin-photodynamic therapy for ... combination approach blends immunotherapy with Bremachlorin-photodynamic therapy for advanced ... combination approach blends immunotherapy with Bremachlorin-photodynamic therapy for advanced ... has found that immunotherapy can be efficiently combined ...
(Date:11/26/2015)... 2015 3D bioprinting market is ... a new report by Grand View Research Inc. Rising prevalence ... demands kidney transplantation is expected to boost the market growth, ... organ transplantation. --> 3D bioprinting market is ... a new report by Grand View Research Inc. Rising prevalence ...
Breaking Medicine Technology: